Arena Pharmaceuticals to continue clinical trial for obesity
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) said today that it is moving forward with its clinical trial for lorcaserin hydrochloride for the treatment of obesity following a review by an independent Echocardiographic Data Safety Monitoring Board. Shares gained 10.1%, or $0.64, to $6.95 in pre-market trading.
For detailed price information and recent news stories about Arena Pharmaceuticals, click ARNA.
